2026-01-12
mmuneOnco Biopharmaceuticals' Timdarpacept (IMM01) Receives NMPA Approval for Clinical Trial in Atherosclerosis
Shanghai, China, January 12, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the clinical trial application for its self-developed timdarp
View more
2026-01-09
ImmuneOnco to Attend 44th Annual J.P. Morgan Healthcare Conference and Present Corporate Overview at Biotech Showcase™
Shanghai, China, January 9, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that a three-person delegation from the company will attend the 44t
View more
2026-01-06
ImmuneOnco Regains Global Rights to IMM2510/AXN-2510 and IMM27M/AXN-27M Following Axion Bio's Discontinuation
SHANGHAI, January 6, 2026 -- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc.,
View more
